Role of prolactin in modulating the effects of tamoxifen on growth of the dunning R3327 rat prostate adenocarcinoma
- 1 January 1987
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 10 (1) , 57-67
- https://doi.org/10.1002/pros.2990100109
Abstract
Tamoxifen (TAM) has previously been shown to inhibit growth of the Dunning R3327 rat prostate adenocarcinoma and to elevate serum prolactin levels. The purpose of this study was to determine the role of prolactin in modulating the effects of tamoxifen on growth of the R3327 prostatic adenocarcinoma. Intact and castrated Copenhagen‐Fischer male rats bearing the Dunning R3327 rat prostatic tumor were divided into groups and injected sc five times per week for 16 weeks as follows: vehicle; TAM (0.5 mg/kg); haloperidol (HALO; 0.5 mg/kg); bromocryptine (CB‐154; 5 mg/kg); TAM plus HALO; or TAM plus CB‐154. In both intact and castrated rats, agents that either raised (HALO) or lowered (CB‐154) serum prolactin had little effect on prostatic tumor growth when administered singly. In intact rats, average tumor diameter in vehicle‐treated controls increased 421% 16 weeks after the start of the experiment, and treatment with TAM or TAM plus HALO reduced this tumor growth by approximately one‐half. Interestingly, CB‐154 administered in combination with TAM completely blocked TAM inhibition of tumor growth in intact rats. In contrast to these results in intact rats, average tumor diameter increased 129% in TAM‐ and 118% in TAM plus HALO‐treated castrated rats and was significantly greater than the characteristic retardation of tumor growth (49% increase) that occurred in the vehicle‐treated castrate controls. In addition, combined treatment of TAM plus CB‐154 in castrate rats resulted in an even greater increase (188%) in average tumor diameter. The inhibitory effect of TAM on R3327 prostatic tumor growth in intact rats appears to be an indirect effect resulting from its ability to reduce serum testosterone levels. In contrast, the stimulatory effect of TAM in castrate rats appears to result directly from an estrogen‐like action, which can directly enhance prostatic tumor growth in the presence of low levels of circulating androgens; this stimulatory effect of TAM is more pronounced when prolactin levels are suppressed by CB‐154. Clearly, castration alone is more effective than TAM therapy alone or in combination with castration in the retardation of the growth of the androgen‐dependent R3327 prostatic tumor in rats.Keywords
This publication has 22 references indexed in Scilit:
- A comparison of estrogen and androgen receptor levels in human prostatic tissue from patients with non-metastatic and metastatic carcinoma and benign prostatic hyperplasiaThe Journal of Steroid Biochemistry and Molecular Biology, 1985
- Characterization of estrogen-induced progestin binding in cytosol of the R3327 prostatic carcinoma of the ratThe Journal of Steroid Biochemistry and Molecular Biology, 1985
- Biphasic Response of the Rat Lateral Prostate to Increasing Levels of Serum Prolactin 1Biology of Reproduction, 1983
- Rapid endocrine effects of tamoxifen and testolactone in prostatic carcinoma patientsThe Prostate, 1982
- Effect of perphenazine on growth and zinc-65 uptake of the rat prostatic adenocarcinoma, R 3327The Prostate, 1982
- Endocrine control and physiology of the prostateThe Prostate, 1980
- RESPONSE TO TAMOXIFEN IN DRUG-RESISTANT PROSTATIC CARCINOMAThe Lancet, 1979
- Nonsteroidal antiestrogens: Their biological effects and potential mechanisms of actionJournal of Toxicology and Environmental Health, 1978
- Direct Inhibition by Ergocornine of Pituitary Prolactin ReleaseEndocrinology, 1971
- Radioimmunoassay for Rat ProlactinExperimental Biology and Medicine, 1969